Effect of St John's wort on the disposition of fexofenadine in the isolated perfused rat liver

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 8, 2009, Pages 1037-1042

  Turkanovica, Jasmina ^a   Ngo, Suong N T ^b   Milne, Robert W ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b CHARLES DARWIN UNIVERSITY   (Australia)

Author keywords

Fexofenadine; Hepatic transport; Induction; Organic anion transporting polypeptide; P glycoprotein; St john's wort

Indexed keywords

CYCLOSPORIN A; FEXOFENADINE; HYPERICUM PERFORATUM EXTRACT; CYCLOSPORIN; DRUG DERIVATIVE; GLYCOPROTEIN P; HISTAMINE H1 RECEPTOR ANTAGONIST; PLANT EXTRACT; TERFENADINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG POTENTIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOLATED LIVER; LIVER HOMOGENATE; LIVER PERFUSION; MALE; NONHUMAN; RAT; ANIMAL; CHEMISTRY; DRUG EFFECT; DRUG INTERACTION; HYPERICUM; LIVER; LIVER CELL; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; DRUG INTERACTIONS; HEPATOCYTES; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HYPERICUM; LIVER; MALE; P-GLYCOPROTEIN; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; TERFENADINE;

EID: 70249134049     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp/61.08.0007     Document Type: Article

References (32)

1. Josey ES, Tackett RL. St. John's wort: a new alternative for depression? Int J Clin Pharmacol Ther 1999; 37: 111-119.
2. Woelk H. Comparison of St John's wort and imipramine for treating depression: randomised clinical trial. BMJ 2005; 321: 536-539.
3. Fugh-Berman A. Herb-drug interactions. Lancet 2000; 355: 134-138.
4. Henderson L et al. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002; 54: 349-356.
5. Durr D et al. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68: 598-604.
6. Shibayama Y et al. St. John's Wort (Hypericum perforatum) induces overexpression of multidrug resistance protein 2 (MRP2) in rats: a 30-day ingestion study. Food Chem Toxicol 2004; 42: 995-1002.
7. Kageyama M et al. Relationship between excretion clearance of rhodamine 123 and P-glycoprotein (Pgp) expression induced by representative Pgp inducers. Biol Pharm Bull 2006; 29: 779-784.
8. Garrovo C et al. St John's wort modulation and developmental expression of multidrug transporters in the rat. Phytother Res 2006; 20: 468-473.
9. Kamath AV et al. Effect of fruit juices on the oral bioavailibility of fexofenadine in rats. J Pharm Sci 2004; 94: 233-239.
10. Lippert C et al. Mass balance and pharmacokinetics of MDL 16,455A in healthy male volunteers. Pharm Res 1996; 12: S390.
11. Milne RW et al. Hepatic disposition of fexofenadine: influence of the transport inhibitors erythromycin and dibromosulphothalein. Pharm Res 2000; 17: 1511-1515.
12. Dresser GK et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002; 71: 11-20.
13. Tong Y et al. Alteration of fexofenadine disposition in the rat isolated perfused liver following injection of bacterial lipopolysaccharide. Clin Exp Pharmacol Physiol 2006; 33: 685-689.
14. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2002; 55: 3-29.
15. Mealey K. Therapeutic implications of the MDR-1 gene. J Vet Pharmacol Ther 2004; 27: 257-264.
16. Varma MVS et al. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 2003; 48: 347-359.
17. Leslie EM et al. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2 and BCRP (ABCG2) in tissue defence. Toxicol Appl Pharmacol 2005; 204: 216-237.
18. Pizzagalli F et al. Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol 2002; 16: 2283-2296.
19. Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007; 8: 787-802.
20. Kim RB. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Invest 2003; 33: 1-5.
21. Linde K et al. St John's wort for depression - an overview and meta-analysis of randomised clinical trials. BMJ 1996; 313: 253-258.
22. Schwarz UI et al. Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception. Br J Clin Pharmacol 2003; 55: 112-113.
23. Schwarz UI et al. Induction of intestinal P-glycoprotein by St John's Wort reduces the oral bioavailibility of talinolol. Clin Pharmacol Ther 2007; 81: 669-678.
24. Treiber A et al. Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetc interaction between bosentan and cyclosporin A in the rat. J Pharmacol Exper Ther 2004; 308: 1121-1129.
25. Matsushima S et al. Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol 2008; 73: 1474-1483.
26. Tian X et al. Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice. Drug Metab Dispos 2008; 36: 61-64.
27. Swift BD et al. Evaluation of transport proteins responsible for biliary excretion of fexofenadine in rats and humans. AAPS Journal 2008; 10(Suppl. 2): Abstr. 997.
28. Chen AS et al. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol 1999; 56: 1219-1228.
29. Moore LB et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Nat Acad Sci 2000; 97: 7500-7502.
30. Wurglics M, Schubert-Zsilavecz M. Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet 2006; 45: 449-468.
31. Bauer B et al. In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Mol Pharmacol 2006; 70: 1212-1219.
32. Mueller SC et al. Effect of St John's wort dose and preparations on the pharamcokinetics of digoxin. Clin Pharmacol Ther 2004; 75: 546-557.